Stifel analyst Annabel Samimy downgraded Revance Therapeutic (NASDAQ: RVNC) from Buy to Hold with a price target of $6.66 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

William Blair Downgrades Revance Therapeutic (RVNC) to Market PerformAugust 12, 2024 11:12 AM RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown LaboratoriesAugust 12, 2024 9:34 AM RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown LaboratoriesAugust 12, 2024 9:34 AM Form 8-K Revance Therapeutics, For: Aug 11August 12, 2024 9:21 AM Crown Laboratories and Revance (RVNC) Announce Entry Into Merger AgreementAugust 12, 2024 8:00 AM Crown Laboratories and Revance Announce Entry Into Merger AgreementAugust 12, 2024 8:00 AM Revance Therapeutics (RVNC) Halted, News PendingAugust 12, 2024 7:56 AM Form 8-K Revance Therapeutics, For: Aug 08August 9, 2024 9:00 AM Revance Therapeutic (RVNC) PT Lowered to $20 at StifelAugust 9, 2024 8:19 AM Form 10-Q Revance Therapeutics, For: Jun 30August 8, 2024 4:35 PM Revance Therapeutics (RVNC) Reports In-Line Q2 EPS, provides guidanceAugust 8, 2024 4:32 PM Form 8-K Revance Therapeutics, For: Aug 08August 8, 2024 4:10 PM Revance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateAugust 8, 2024 4:06 PM